Published in Antimicrob Agents Chemother on May 01, 1989
Effects of magnesium-aluminum hydroxide and calcium carbonate antacids on bioavailability of ofloxacin. Antimicrob Agents Chemother (1990) 1.28
Effect of antacid medication on the pharmacokinetics of temafloxacin. Clin Pharmacokinet (1992) 1.05
Pharmacokinetics of cefpodoxime proxetil and interactions with an antacid and an H2 receptor antagonist. Antimicrob Agents Chemother (1992) 1.00
Fluoroquinolones: interaction profile during enteral absorption. Drugs (1993) 0.91
Effect of sucralfate on absorption of norfloxacin and ofloxacin. Antimicrob Agents Chemother (1994) 0.87
Effects of magnesium-aluminum hydroxide antacid on absorption of rufloxacin. Antimicrob Agents Chemother (1993) 0.84
Effect of oral antacids on disposition of intravenous enoxacin. Antimicrob Agents Chemother (1993) 0.84
Effects of antacids, ferrous sulfate, and ranitidine on absorption of DR-3355 in humans. Antimicrob Agents Chemother (1992) 0.83
[Enoxacin--comparative pharmacokinetics and tissue penetration]. Infection (1989) 0.81
The relative bioavailability of temafloxacin administered through a nasogastric tube with and without enteral feeding. Clin Pharmacokinet (1992) 0.77
Effect of an antacid containing magnesium and aluminum on absorption, metabolism, and mechanism of renal elimination of pefloxacin in humans. Antimicrob Agents Chemother (1994) 0.77
A limited number of prescribed drugs account for the great majority of drug-drug interactions. Eur J Clin Pharmacol (2014) 0.77
Lack of pharmacokinetic interaction between linezolid and antacid in healthy volunteers. Antimicrob Agents Chemother (2006) 0.77
Interaction study of lomefloxacin and ciprofloxacin with omeprazole and comparative pharmacokinetics. Antimicrob Agents Chemother (1995) 0.76
Effects of milk and food on the absorption of enoxacin. Br J Clin Pharmacol (1995) 0.75
Effect of enrofloxacin on digoxin clearance and steady-state serum concentrations in dogs. Can J Vet Res (1991) 0.75
Oral absorption of ofloxacin administered together with aluminum. Antimicrob Agents Chemother (1994) 0.75
Ionization and divalent cation dissociation constants of nalidixic and oxolinic acids. Bioinorg Chem (1978) 2.09
Effects of antacids and dialysate dwell times on multiple-dose pharmacokinetics of oral ciprofloxacin in patients on continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother (1987) 1.87
Effect of food on enoxacin absorption. Antimicrob Agents Chemother (1987) 1.46
The effect of single intravenous doses of cimetidine or ranitidine on gastric secretion. Clin Pharmacol Ther (1986) 1.19
The UCSC Genome Browser Database. Nucleic Acids Res (2003) 32.84
Blocks of limited haplotype diversity revealed by high-resolution scanning of human chromosome 21. Science (2001) 15.54
The UCSC genome browser database: update 2007. Nucleic Acids Res (2006) 13.04
The UCSC Genome Browser Database: update 2006. Nucleic Acids Res (2006) 11.05
Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother (1993) 7.05
NF-AT components define a family of transcription factors targeted in T-cell activation. Nature (1994) 4.90
CSTRIP, a fortran IV computer program for obtaining initial polyexponential parameter estimates. J Pharm Sci (1976) 4.75
Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples. Lancet (1999) 4.02
Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group. Antimicrob Agents Chemother (1994) 3.73
Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in rat and human cells. Arch Toxicol (2000) 3.46
Pharmacokinetic and clinical studies in patients with cimetidine-associated mental confusion. Lancet (1979) 2.71
A safe peritoneal access device for repeated peritoneal dialysis. JAMA (1970) 2.68
The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin Pharmacokinet (1995) 2.66
Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication. Arch Intern Med (1989) 2.56
Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening. J Clin Pharmacol (1996) 2.37
Role for dual individualization with cefmenoxime. Am J Med (1984) 2.29
Pharmacokinetics and safety of trovafloxacin (CP-99,219), a new quinolone antibiotic, following administration of single oral doses to healthy male volunteers. J Antimicrob Chemother (1995) 2.29
The management of diabetes during surgery. Br J Anaesth (1979) 2.20
Noncompartmental determination of the steady-state volume of distribution during multiple dosing. J Pharm Sci (1984) 2.20
Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother (1998) 2.19
Severity of asymptomatic carotid stenosis and risk of ipsilateral hemispheric ischaemic events: results from the ACSRS study. Eur J Vasc Endovasc Surg (2005) 2.19
Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin. Clin Pharmacol Ther (1989) 2.08
Methylated trivalent arsenic species are genotoxic. Chem Res Toxicol (2001) 2.03
The folding and stability of titin immunoglobulin-like modules, with implications for the mechanism of elasticity. Biophys J (1995) 1.93
NFATc3, a lymphoid-specific NFATc family member that is calcium-regulated and exhibits distinct DNA binding specificity. J Biol Chem (1995) 1.91
Gentamicin disposition and tissue accumulation on multiple dosing. J Pharmacokinet Biopharm (1977) 1.90
Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin. Antimicrob Agents Chemother (1993) 1.88
Determination of trivalent methylated arsenicals in biological matrices. Toxicol Appl Pharmacol (2001) 1.84
In vitro selection of resistant Helicobacter pylori. Antimicrob Agents Chemother (1990) 1.83
Effect of haematocrit on cerebral blood-flow in man. Lancet (1977) 1.80
Tissue persistence of gentamicin in man. JAMA (1977) 1.79
Cerebral blood-flow in polycythaemia. Lancet (1977) 1.79
Reduction and binding of arsenate and dimethylarsinate by glutathione: a magnetic resonance study. Chem Biol Interact (1994) 1.77
In vivo generation of human dendritic cell subsets by Flt3 ligand. Blood (2000) 1.76
Sucralfate reduces the gastrointestinal absorption of norfloxacin. Antimicrob Agents Chemother (1989) 1.74
Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada. Diagn Microbiol Infect Dis (1998) 1.71
Evidence for an association between rheumatoid arthritis and autoimmune endocrine disease. Ann Rheum Dis (1983) 1.64
Nervous system involvement in ankylosing spondylitis. Br Med J (1974) 1.62
Clinical NMR imaging of the brain: 140 cases. AJR Am J Roentgenol (1982) 1.61
The relationship between coal rank and the prevalence of pneumoconiosis. Br J Ind Med (1979) 1.60
Enhanced biotransformation of theophylline in marihuana and tobacco smokers. Clin Pharmacol Ther (1978) 1.59
Excretion of arsenic in urine as a function of exposure to arsenic in drinking water. Environ Health Perspect (1999) 1.56
Factors affecting theophylline clearances: age, tobacco, marijuana, cirrhosis, congestive heart failure, obesity, oral contraceptives, benzodiazepines, barbiturates, and ethanol. J Pharm Sci (1979) 1.56
Benchmark analysis of strategies hospitals use to control antimicrobial expenditures. Am J Health Syst Pharm (1996) 1.53
Liquid-chromatographic determination of ciprofloxacin in serum and urine. Clin Chem (1985) 1.52
Antibiotic tissue penetration and its relevance: models of tissue penetration and their meaning. Antimicrob Agents Chemother (1991) 1.52
Accumulation pharmacokinetics of tobramycin. Antimicrob Agents Chemother (1978) 1.51
Antibiotic tissue penetration and its relevance: impact of tissue penetration on infection response. Antimicrob Agents Chemother (1991) 1.50
Gentamicin tissue accumulation and nephrotoxic reactions. JAMA (1978) 1.49
Renal clearance and tissue accumulation of gentamicin. Clin Pharmacol Ther (1977) 1.48
Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects. Clin Pharmacol Ther (1996) 1.48
Arctic marine ecosystem contamination. Sci Total Environ (1992) 1.44
Comparison of two methods for determining in vitro postantibiotic effects of three antibiotics on Escherichia coli. Antimicrob Agents Chemother (1988) 1.44
Trends in antibiotic utilization and bacterial resistance. Report of the National Nosocomial Resistance Surveillance Group. Diagn Microbiol Infect Dis (1992) 1.43
Comparative inhibition of yeast glutathione reductase by arsenicals and arsenothiols. Chem Res Toxicol (1997) 1.43
Racial differences in the incidence of gout. The role of hypertension. Arthritis Rheum (1995) 1.43
Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infections. Int J Antimicrob Agents (2000) 1.43
Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother (1997) 1.42
Alteration of theophylline clearance and half-life by cimetidine in normal volunteers. Ann Intern Med (1981) 1.41
Influence of fluoroquinolone purchasing patterns on antimicrobial expenditures and Pseudomonas aeruginosa susceptibility. Am J Health Syst Pharm (1999) 1.41
Factors predisposing to the development of progressive massive fibrosis in coal miners. Br J Ind Med (1981) 1.40
Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Ann Intern Med (1991) 1.40
Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra Arthritis Study Group. Arthritis Rheum (1996) 1.39
Brain CT infarction in patients with carotid atheroma. Does it predict a future event? Int Angiol (2001) 1.39
Periodic hypothermia. Br Med J (1973) 1.39
Inhibition of norfloxacin absorption by antacids. Antimicrob Agents Chemother (1990) 1.38
The metabolism of diphenylhydantoin (Dilantin) following once-daily administration. Neurology (1972) 1.36
Effect of multiple dose oral ciprofloxacin on the pharmacokinetics of theophylline and indocyanine green. J Antimicrob Chemother (1987) 1.33
Relative safety of intravenous digital subtraction angiography over other methods of carotid angiography and impact on clinical management of cerebrovascular disease. Br J Radiol (1989) 1.33
Haemodialysis and cerebral oedema. Nephron (2001) 1.33
Biomechanics of skull fracture. J Neurotrauma (1995) 1.33
Irregularly shaped small shadows on chest radiographs, dust exposure, and lung function in coalworkers' pneumoconiosis. Br J Ind Med (1988) 1.32
Obesity and hypertension in a longitudinal study of black physicians: the Meharry Cohort Study. J Chronic Dis (1986) 1.30
Gout and risk for subsequent coronary heart disease. The Meharry-Hopkins Study. Arch Intern Med (1997) 1.30
Arsenicals inhibit thioredoxin reductase in cultured rat hepatocytes. Chem Res Toxicol (2001) 1.30
Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs are similar. Antimicrob Agents Chemother (1994) 1.30
Continuous lumbar epidural analgesia using bupivicaine: a study of the fetus and newborn child. J Obstet Gynaecol Br Commonw (1971) 1.29
The pharmacokinetics of etanercept in healthy volunteers. Ann Pharmacother (2000) 1.28
The quinolones: an overview and comparative appraisal of their pharmacokinetics and pharmacodynamics. J Clin Pharmacol (1988) 1.28
Presynaptic cholinergic dysfunction in patients with dementia. J Neurochem (1983) 1.28
Comparative nephrotoxicity of gentamicin and tobramycin: pharmacokinetic and clinical studies in 201 patients. Antimicrob Agents Chemother (1981) 1.27
Methylarsenicals and arsinothiols are potent inhibitors of mouse liver thioredoxin reductase. Chem Res Toxicol (1999) 1.26
Report of laparoscopic cholecystectomy in two patients with left-sided gallbladders. JSLS (2001) 1.26
Dose-ranging pharmacokinetic study of ciprofloxacin after 200-, 300-, and 400-mg intravenous doses. Ann Pharmacother (1992) 1.25
An examination of the micromechanics of failure of bone and antler by acoustic emission tests and Laser Scanning Confocal Microscopy. Med Eng Phys (1994) 1.24
Whole blood viscosity and cerebral blood flow. Stroke (1982) 1.24
NMR imaging of the brain using spin-echo sequences. Clin Radiol (1982) 1.24
Metabolism of arsenic in primary cultures of human and rat hepatocytes. Chem Res Toxicol (1999) 1.22
An intravenous 133xenon clearance technique for measuring cerebral blood flow. J Neurol Sci (1979) 1.22
Methicillin distribution in serum and extravascular fluid and its relevance to normal and damaged heart valves. Antimicrob Agents Chemother (1981) 1.22
Preservation of autoregulation of cerebral blood flow in autonomic failure. J Neurol Sci (1980) 1.22
Urinary casts as an indicator of renal tubular damage in patients receiving aminoglycosides. Antimicrob Agents Chemother (1979) 1.21
Elimination of alcohol from human blood. J Pharm Sci (1976) 1.20
Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics. Am J Med (1991) 1.19
In vitro pharmacodynamics of piperacillin, piperacillin-tazobactam, and ciprofloxacin alone and in combination against Staphylococcus aureus, Klebsiella pneumoniae, Enterobacter cloacae, and Pseudomonas aeruginosa. Antimicrob Agents Chemother (1995) 1.19
Animal model distinguishing in vitro from in vivo carbenicillin-aminoglycoside interactions. Antimicrob Agents Chemother (1980) 1.19
An evaluation of the absorption characteristics of different chloramphenicol preparations in normal human subjects. Clin Pharmacol Ther (1968) 1.18
Presence and implications of chemical contaminants in the freshwaters of the Canadian Arctic. Sci Total Environ (1992) 1.17